Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 10341-10349

  Yu, Guiping ^a   Zhong, Ning ^b   Chen, Guoqiang ^a   Huang, Bin ^a   Wu, Song ^a  

^a JIANGYIN PEOPLE S HOSPITAL   (China)

^b KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

Author keywords

Cisplatin; Lung cancer; miR 34a; Phosphatidylethanolamine binding protein 4

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MICRORNA; MIRN34 MICRORNA, HUMAN; PE-BINDING PROTEIN 4, HUMAN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84922392884     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2284-3     Document Type: Article

References (42)

1. Marshall HM, Bowman RV, Yang IA, Fong KM, Berg CD. Screening for lung cancer with low-dose computed tomography: a review of current status. J Thorac Dis. 2013;5:S524-39.
2. Wakelee H. Management of early stage non-small cell lung cancer. Transl Lung Cancer Res. 2013;2:315.
3. Templeton AK,Miyamoto S, Babu A, Munshi A, Ramesh R. Cancer stem cells: progress and challenges in lung cancer. Stem Cell Investigation. 2014;1:99.
4. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10-21.
5. Park BJ. Robotic lobectomy for non-small cell lung cancer (NSCLC): multi-registry study of long-term oncologic results. Ann Cardiothorac Surg. 2012;1(1):24-6.
6. Bar J, Urban D, Borshtein R, Nechushtan H, Onn A. EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy. Chin Clin Oncol. 2013;2:2.
7. Zhan P, Qian Q,Wan B, Yan TD, Yu LK. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a metaanalysis. Transl Cancer Res. 2013;2:25-32.
8. Bernier I, Jolles P. Purification and characterization of a basic 23 kDa cytosolic protein from bovine brain. Biochim Biophys Acta. 1984;790(2):174-81.
9. Garcia R, Grindlay J, Rath O, et al. Regulation of human myoblast differentiation by PEBP4. EMBO Rep. 2009;10(3):278-84.
10. Amaya I , Ratcliffe OJ, Bradley DJ. Expression of CENTRORADIALIS (CEN) and CEN-like genes in tobacco reveals a conserved mechanism controlling phase change in diverse species. Plant Cell. 1999;11(8):1405-18.
11. Erttmann KD, Gallin MY. Onchocerca volvulus: identification of cDNAs encoding a putative phosphatidyl-ethanolamine-binding protein and a putative partially processed mRNA precursor. Gene. 1996;174(2):203-7.
12. Wilson R, Ainscough R, Anderson K, et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature. 1994;368(6466):32-8.
13. Kikuchi R, Kawahigashi H, Ando T, et al. Molecular and functional characterization of PEBP genes in barley reveal the diversification of their roles in flowering. Plant Physiol. 2009;149(3):1341-53.
14. Odabaei G, Chatterjee D, Jazirehi AR, et al. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169-200.
15. Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 2008;12(10):1275-87.
16. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem. 2005;94(2):273-8.
17. Sagisaka T, Matsukawa N, Toyoda T, et al. Directed neural lineage differentiation of adult hippocampal progenitor cells via modulation of hippocampal cholinergic neurostimulating peptide precursor expression. Brain Res. 2010;1327:107-17.
18. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401(6749):173-7.
19. Corbit KC, Trakul N, Eves EM, et al. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003;278(15):13061-8.
20. Shemon AN, Heil GL, Granovsky AE, et al. Characterization of the Raf kinase inhibitory protein (RKIP) binding pocket: NMR-based screening identifies small-molecule ligands. PLoS One. 2010;5(5): e10479.
21. Yu GP, Huang B, Chen GQ, et al. PEBP4 gene expression and its significance in invasion and metastasis of non-small cell lung cancer. Tumour Biol. 2012;33(1):223-8.
22. Wang X, Li N, Liu B, et al. A novel human phosphatidylethanolaminebinding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem. 2004;279(44): 45855-64.
23. Liu H, Qiu J, Li N, et al. Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasomedependent ERalpha degradation via association with Src. J Biol Chem. 2010;285(29):21934-42.
24. Qiu J, Xiao J, Han C, et al. Potentiation of tumor necrosis factor-alphainduced tumor cell apoptosis by a small molecule inhibitor for antiapoptotic protein hPEBP4. J Biol Chem. 2010;285(16):12241-7.
25. Yu GP, Chen GQ, Wu S, et al. The expression of PEBP4 protein in lung squamous cell carcinoma. Tumour Biol. 2011;32(6):1257-63.
26. Zhang J, Wang L, Xing Z, et al. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2011;10(4):272-82.
27. Zhang J, Liu D, Li Y, et al. Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem. 2009;9(11):1357-66.
28. Shen Z, Zhan G,Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol. 2012;29(4):2473-80.
29. Link A, Kupcinskas J, Wex T, et al. Macro-role of microRNA in gastric cancer. Dig Dis. 2012;30(3):255-67.
30. Wong MY, Yu Y, Walsh WR, et al. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol. 2011;38(5):1189-95.
31. O'Day E, Lal A.MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201.
32. Cha YH, Kim NH, Park C, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11(7):1273- 81.
33. Balca-Silva J, Neves SS, Goncalves AC, et al. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 2012;32(5):1603-9.
34. Hui C, Yujie F, Lijia Y, et al.MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1- methyl-1-nitrosourea-induced breast carcinogenesis. Breast Cancer Res. 2012;14(3):R80.
35. Zhang LN, Li JY, XuW. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther. 2013;20(1):1-7.
36. Shimizu K, Okita R, Nakata M. Clinical significance of the tumor microenvironment in non-small cell lung cancer. Ann Transl Med. 2013;1:20.
37. Wang X, Li N, Li H, et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to tumor necrosis factor-alpha-induced apoptosis and cell growth arrest. Clin Cancer Res. 2005;11(20):7545-53.
38. Li P,Wang X, Li N, et al. Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways. Int J Mol Med. 2006;18(3):505-10.
39. Ji X,Wang Z, Sarkar FH, et al. Delta-tocotrienol augments cisplatininduced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway. Anticancer Res. 2012;32(7):2647-55.
40. Yu G, Shen Z, Chen G, et al. PEBP4 enhanced HCC827 cell proliferation and invasion ability and inhibited apoptosis. Tumour Biol. 2013;34(1):91-8.
41. Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012;7(5): e37601.
42. Li L, Yuan L, Luo J, et al. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013;13(2):109-17.